Navigation Links
Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Date:4/24/2008

EVRY, France, April 24 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company today announced that it has successfully injected the first patient in a Phase I clinical trial using CORTIJECT(R), an ophthalmic injectable emulsion based on EYEJECT(R) technology platform containing a corticosteroid prodrug for the treatment of Diabetic Macular Edema (DME). This trial, which will enrol a total of 15 patients, is designed to evaluate the safety and to observe the efficacy trend of CORTIJECT(R). The patients will be monitored for a period of twelve months following injection. Company's Investigational New Drug Application (IND) to conduct this Phase I clinical trial has been granted by the U.S. Food and Drug Administration (FDA) in January 2008 (cf. Novagali Pharma Press Release issued on January 18th, 2008).

"This first injection in patient is a crucial step toward the clinical development of our state-of-the-art technology for the posterior segment of the eye that can be used to develop new treatments for retinopathies" said Jerome Martinez, Pharm.D., Novagali Pharma Chief Executive Officer. "Thanks to EYEJECT(R) technology, CORTIJECT(R) is a major move with the optimized use of corticosteroids for the back of the eye expected to combine ease of use, sustained release and ocular safety. Administering this emulsion through a single injection can offer real medical value to both physicians and patients."

Investigators for this open-label, dose-escalation study will treat patients suffering from DME with a single intravitreal injection (inside the eye) of CORTIJECT(R) formulation. The trial will include 3 treatment arms with patients receiving one of three doses of Novagali Corticosteroid prodrug. Each administration of CORTIJECT(R) will provide the patient with exposure to the compound for approximately nine months.

About Novagali Pharma : http://www.novagali.com


'/>"/>

SOURCE Novagali Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Mass. , Oct. 30, 2014 Boston ... to participate in the 2014 Credit Suisse Annual Healthcare ... Phoenix , AZ.  Dan Brennan , executive ... presentation about the company beginning at approximately 8:00 a.m. ... A live webcast of the presentation and question ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, ... devoted to bringing new products to market, has ... called TetraStem. TetraStem is a topical liquid tetracycline-based ... system that can convert oral medication active ingredients ... as a first aid antibiotic to help prevent ...
(Date:10/30/2014)... , Oct. 30, 2014 CVS Health (NYSE: ... new clinical affiliations with three leading regional health systems to ... The collaborating health systems include Baptist Health System in ... which include Commonwealth Health in Pennsylvania , ... Arizona , and Tennova Healthcare in Tennessee ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4
(Date:10/30/2014)... Five months after their expansion, the ... announces new branding and a website to accompany their ... David Mepham’s promotion to name partner earlier this year, ... include Mepham’s name and better reflect their combined litigation ... the decision to implement new branding reflects Hodgkinson Street ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... IL (PRWEB) October 30, 2014 Dr. Joseph ... a new website for his practices; OB GYN in ... IL . This website contains important information about each ... as well as downloadable patient forms in English and Spanish. ... and the service pages on the website provide Dr. Furlin’s ...
(Date:10/30/2014)... REV'D Provision Co. announced today that REV’D® ... unique service called, The Feed . The Feed ... athlete. The Feed has taken the nutritional knowledge used ... to pass that information on to the everyday athlete. ... on The Feed!” says REV’D® marketing manager Matt O’Connor. ...
(Date:10/30/2014)... Sound Telecom, a leader in the call center industry, just ... they wonder, “Should I use an answering service?” The graphic ... a series of yes or no questions that ultimately ends ... many considerations and scenarios that come into play when deciding ... This decision infographic serves as a bit of a map ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2
... TAMPA, Fla., Sept. 1 Amazing medical advancements are made ... been before. As a result, people are living longer lives. While ... population and new medical discoveries has created a huge demand for ... -- from one-year Licensed Practical Nurse (LPN) certifications ...
... September 1, 2009Patients with advanced illnesses more than doubled ... health plan made hospice care more readily accessible, according ... Journal of Palliative Medicine , a peer-reviewed publication ... of Palliative Medicine is the official journal of ...
... a myriad of diseases, including cancer, heart disease and ... for delivering genes to cells both efficiently and safely ... University researchers has introduced the power of nanodiamonds as ... in one approach: enhanced delivery efficiency along with outstanding ...
... , , CHICAGO, Sept. ... "Project Runway," launched a new online video series, called " Living ... national HIV and AIDS education initiative. The Living Positive By ... videos aim to encourage thoughtful conversations about HIV and AIDS, to ...
... , BOSTON, Sept. 1 AMR ... supply chain and its supporting technologies, is proud to announce that ... research for the firm, was named to PharmaVOICE,s list of the ... , , According to PharmaVOICE,s July/August edition, "One ...
... CINCINNATI, Sept. 1 Healthy Advice ... patient-education programs has announced that SIGVARIS, the world,s leading ... the Skin Care Network to broaden their educational coverage. ... an ideal place to increase the awareness of Chronic ...
Cached Medicine News:Health News:Saving Lives Is a Growth Industry 2Health News:Saving Lives Is a Growth Industry 3Health News:Expanded insurance benefits break down barriers to hospice care, according to new study 2Health News:Promise of nanodiamonds for safer gene therapy 2Health News:Promise of nanodiamonds for safer gene therapy 3Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 2Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 3Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 2Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 3Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 2Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 3
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
Includes conservation device, matched regulator, standard supply tubing, cannula, carrying case, batteries, and instruction booklet....
Medicine Products: